1Zipursky A, Poon A, Doyle J. Leukemia in Down syndrome: a review, Pediatr Hematol Oncol, 1992 ;9(2) :139 -49.
2Lange B. The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol, 2000 ;110(3) :512 -24.
3Taub JW, Ravindranath Y. Down syndrome and the transient myeloproliferative disorder: why is it transient? J Pediatr Hematol Oncol,2002 ;24(1) :6 -8.
4Zipursky A. Transient leukaemia - a benign form of leukaemia in newborn infants with trisomy 21. Br J Haematol, 2003 ;120(6) :930-8.
5Gamis AS, Hilden JM. Transient myeloproliferative disorder, a disorder with too few data and many unanswered questions: does it contain an important piece of the puzzle to understanding hematopoiesis and acute myelogenous leukemia? J Pediatr Hematol Oncol, 200224(1 ):2-5.
7Carpenter E,Valverde -Garduno V,Sternberg A . et al. GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder. Br J Haematol,2005 ;128(4) :548 -51.
8Magalhaes IQ, Splendore A, Emerenciano M, et al, Transient neonatal myeloproliferative disorder without Down syndrome and detection of GATA1 mutation, J Pediatr Hematol Oneol, 2005 ;27( 1 ) :50 -2.
9Weiss MJ, Yu C, Orkin SH. Erythroid - cell - specific properties of transcription factor GATA - 1 revealed by phenotypic rescue of a gene-targeted cell line. Mol Cell Biol, 1997 ;17(3) :1642-51.
10Shimizu R, Takahashi S, Ohneda K, et al . In vivo requirements for GATA - 1 functional domains during primitive and definitive erythropoiesis. EMBO J, 2001 ;20(18) :5250 -60.
